- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000605
Estrogen and Graft Atherosclerosis Research Trial (EAGER)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND:
Coronary atherosclerosis is a major cause of death in women in the United States. Although coronary artery bypass surgery decreases symptomatic and clinical evidence of ischemia, it does not alter the underlying process. Patients may present several years later with recurrent symptoms that may be a result of occlusion of saphenous vein grafts, development of atherosclerotic disease in vein grafts, or progression of underlying disease. Any intervention that can reduce the rate of progression of coronary atherosclerosis following bypass surgery would provide significant benefit for women following bypass surgery and possibly for other women with atherosclerotic disease. Observational studies suggest that postmenopausal estrogen replacement therapy is associated with a reduction in cardiac morbidity.
DESIGN NARRATIVE:
The study was a randomized, double-blind, controlled trial. Subjects were randomized to conjugated estrogen with daily medroxyprogesterone or placebo within two weeks of bypass surgery. Graft occlusion and development of vein graft atherosclerosis were measured by comparing quantitative coronary angiographic and vascular ultrasonic assessment of disease severity and extent performed at six months and three and a half years after randomization. The primary outcome variables included the occurrence of graft occlusion at six months and the change in severity and extent of atherosclerosis in the saphenous vein grafts over three years. The trial determined the influence of hormone replacement therapy on the primary outcome variables.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
Investigators
- Pamela Ouyang, Johns Hopkins University
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Vascular Diseases
- Arterial Occlusive Diseases
- Heart Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Cardiovascular Diseases
- Ischemia
- Arteriosclerosis
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Contraceptive Agents, Male
- Hormones
- Estrogens
- Medroxyprogesterone Acetate
- Medroxyprogesterone
Other Study ID Numbers
- 109
- 5U01HL050840 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
Shanghai Zhongshan HospitalRecruiting
-
Beijing Sungen Biomedical Technology Co., LtdRecruitingAnterior Myocardial InfarctionChina
-
Samsung Medical CenterThe Korean Society of CardiologyNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingMyocardial Infarction (MI)China
-
Myomed Technology (Shaoxing) Co., Ltd.Not yet recruitingSTEMI - ST Elevation Myocardial InfarctionChina
-
Saglik Bilimleri UniversitesiOndokuz Mayis University Training and Research HospitalRecruitingST-elevation Myocardial Infarction (STEMI)Turkey (Türkiye)
-
Qian gengBeijing Chao Yang Hospital; Guizhou Provincial People's Hospital; Beijing Anzhen... and other collaboratorsNot yet recruitingST Elevation (STEMI) Myocardial InfarctionChina
-
Shenyang Northern HospitalRecruitingSTEMI - ST Elevation Myocardial InfarctionChina
-
Rohan DharmakumarCompletedAcute Myocardial Infarction (AMI)India
Clinical Trials on medroxyprogesterone
-
BayerRecruitingEndometrial HyperplasiaChina, United States, Canada
-
Fang WangRecruiting
-
Women's Health Care Clinic, Torrance, CaliforniaCompletedDysfunctional Uterine BleedingUnited States
-
University of California, San DiegoCenter for Research on Environment, Health and Population ActivitiesCompletedLactation | Postpartum Contraception | DMPA | Depot Medroxyprogesterone AcetateNepal
-
Qilu Pharmaceutical Co., Ltd.RecruitingUterine Fibroids | Heavy Menstrual BleedingChina
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedEndometrial CancerUnited States, Norway
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS)Completed
-
Mahidol UniversityCompleted
-
Turku University HospitalCompleted
-
University Hospital of North NorwayNorwegian Cancer Society; Helse NordCompletedEndometrial HyperplasiaNorway